BioLineRx/$BLRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioLineRx
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Ticker
$BLRX
Sector
Primary listing
Employees
22
Headquarters
Hevel Modi'in, Israel
Website
BioLineRx Metrics
BasicAdvanced
$13m
-
-$0.00
0.62
-
Price and volume
Market cap
$13m
Beta
0.62
52-week high
$5.06
52-week low
$2.15
Average daily volume
80k
Financial strength
Current ratio
1.584
Quick ratio
1.413
Long term debt to equity
20.821
Total debt to equity
43.533
Interest coverage (TTM)
-10.08%
Profitability
EBITDA (TTM)
-10.75
Gross margin (TTM)
79.24%
Net profit margin (TTM)
-563.69%
Operating margin (TTM)
-777.46%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-16.55%
Return on equity (TTM)
-46.72%
Valuation
Price to revenue (TTM)
5,551.471
Price to book
2.35
Price to tangible book (TTM)
120.97
Price to free cash flow (TTM)
-998.017
Free cash flow yield (TTM)
-0.10%
Free cash flow per share (TTM)
-0.003
Growth
Revenue change (TTM)
-93.72%
Earnings per share change (TTM)
33.74%
3-year earnings per share growth (CAGR)
-57.14%
10-year earnings per share growth (CAGR)
-35.58%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs